Projected Outcomes of Optimized Statin and Ezetimibe Therapy in US Military Veterans with Coronary Artery Disease

Authors:

Abstract
Despite international guidelines for low-density lipoprotein cholesterol (LDL-C) reduction among patients with atherosclerotic cardiovascular disease (ASCVD), attainment of LDL-C goals often remains suboptimal in clinical practice.1-3 Consequently, opportunities to reduce the risk of death and ASCVD events remain partially unfulfilled. A meta-analysis by the Cholesterol Treatment Trialists’ (CTT) Collaboration4 of randomized clinical trials with statins demonstrated a consistent association between absolute reduction in LDL-C concentration and relative reduction in risk of death and major vascular events. Data from trials with ezetimibe appear to support this relationship with reasonable fidelity.4-6 Treatment with a high-intensity statin regimen results in an approximate 50% LDL-C reduction, while addition of ezetimibe provides a further 13% to 18% reduction in LDL-C.5,7,8 Ezetimibe is recommended as the first nonstatin agent to prescribe when LDL-C goals are not attained with an optimized statin regimen alone.1,2 However, despite ezetimibe’s safety, tolerability, and low cost, its use remains less than 10% in clinical trial populations.9-11 Optimizing lipid-lowering therapy (LLT) with both statin and ezetimibe treatment therefore offers an efficient strategy to achieve substantial LDL-C reduction and consequent clinical benefit.12-16

This publication has 34 references indexed in Scilit: